Limits to Personalized Cancer Medicine
Top Cited Papers
- 29 September 2016
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (13), 1289-1294
- https://doi.org/10.1056/nejmsb1607705
Abstract
The widespread dissemination of the idea of personalized oncology has spread faster than the underlying science. The authors argue that the principles of clinical investigation need to be applied to address the many unanswered questions.This publication has 33 references indexed in Scilit:
- Pharma Firms Push for Sharing of Cancer Trial DataScience, 2012
- Intratumor Heterogeneity: Evolution through Space and TimeCancer Research, 2012
- Raise standards for preclinical cancer researchNature, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2012
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic DrugsJournal of Clinical Oncology, 2011
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001